Phaseline

Targets › IL5

IL5 (Interleukin-5): drug programs, companies and trials

3 programs from 2 companies in 19 trials: 9 Phase 4, 8 Phase 3, 2 Phase 2; Respiratory, Hematology, Immunology; next expected readout Mar 2027.

Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation (By similarity). (UniProt, P05113)

Open in Phaseline: the race on IL5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKDepemokimab
Interleukin-5 inhibitor
IL5Phase 4Nasal Polyps; Eosinophilic Granulomatosis With Polyangiitis; Asthma; Hypereosinophilic Syndrome …Mar 2027
GSKMepolizumab
Interleukin-5 inhibitor
IL5Phase 4Asthma; Chronic Rhinosinusitis with Nasal Polyps; Chronic Rhinosinusitis With Nasal Polyps; Nasal Polyps …Jun 2028
National Jewish HealthReslizumab
Interleukin-5 inhibitor
IL5Phase 2Asthma–

Conditions

Asthma (6) Pulmonary Disease, Chronic Obstructive (3) Chronic Rhinosinusitis With Nasal Polyps (3) Nasal Polyps (2) Eosinophilic Granulomatosis With Polyangiitis (1) Hypereosinophilic Syndrome (1) Chronic Rhinosinusitis with Nasal Polyps (1) Chronic Sinusitis (1) Coronary Artery Disease (1)

Modalities

antibody (3)

Companies

GSK (2) National Jewish Health (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.